Prognostic value of pleural effusion in patients with non-small cell lung cancer
This study was performed to determine whether pleural effusion in patients with advanced non-small cell lung cancer (NSCLC) has a negative impact on survival. We evaluated 12 prognostic factors in 197 patients with stage IIIB or IV NSCLC. Each factor was dichotomized, and survival curves calculated...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 1997-01, Vol.3 (1), p.47-50 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 50 |
|---|---|
| container_issue | 1 |
| container_start_page | 47 |
| container_title | Clinical cancer research |
| container_volume | 3 |
| creator | SUGIURA, S ANDO, Y MINAMI, H ANDO, M SAKAI, S SHIMOKATA, K |
| description | This study was performed to determine whether pleural effusion in patients with advanced non-small cell lung cancer (NSCLC)
has a negative impact on survival. We evaluated 12 prognostic factors in 197 patients with stage IIIB or IV NSCLC. Each factor
was dichotomized, and survival curves calculated by the Kaplan-Meier technique were compared using the log-rank test. The
Cox proportional hazards regression model was used to confirm the significance of each prognostic factor selected by univariate
analysis. We compared the survival times for stage IIIB with pleural effusion with those of stage IIIB without effusion and
stage IV. To determine the impact of the cytological results of the effusion on survival, we compared the survival times for
cytologically positive and negative effusions. Univariate analysis identified eight significant prognostic factors: pleural
effusion, node status, stage, performance status, weight loss, hemoglobin, albumin, and lactate dehydrogenase. Pleural effusion
was selected as a prognostic factor in the multivariate analysis, together with stage, performance status, albumin, and node
status. Median survival times for stage IIIB without effusion, stage IIIB with effusion, and stage IV were 15.3, 7.5, and
5.5 months, respectively (P < 0.0001). Survival time for stage IIIB with effusion was significantly different from that of
stage IIIB without effusion (P = 0.0129) but not from that of stage IV (P = 0.0797). Among patients with effusion, no significant
difference in survival time was observed between cytologically positive and negative effusions. We conclude that pleural effusion
in advanced NSCLC is a prognostic factor. Survival time for stage IIIB with pleural effusion is more similar to that of stage
IV rather than that of stage IIIB without effusion. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_79640028</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79640028</sourcerecordid><originalsourceid>FETCH-LOGICAL-h265t-221fc9b270b902eb60f72ff3c8bc6169b7463be38c38b52b1fb140e77b6b67e33</originalsourceid><addsrcrecordid>eNo9kEtLxDAUhYso4zj6E4Qs1F0hrybtUgZfMOAsdB2SeDONtGlNWgf_vZEZ3Nx74XxczjknxZJUlSwZFdVpvrGsS8wZPS8uUvrEmHCC-aJYNHXGmFgW220cdmFIk7foW3czoMGhsYM56g6Bc3PyQ0A-oFFPHsKU0N5PLQpDKFOvuw5ZyKObww5ZHSzEy-LM6S7B1XGvivfHh7f1c7l5fXpZ32_KNlubSkqJs42hEpsGUzACO0mdY7Y2VhDRGMkFM8Bqy2pTUUOcIRyDlEYYIYGxVXF3-DvG4WuGNKnepz8zOsAwJyUbwTGmdQavj-BsevhQY_S9jj_qWEHWb466TlZ3LuYYPv1jtGp4Q2TGbg9Y63ft3kdQh7wREuhoW8UUUVyyX_vDcu0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79640028</pqid></control><display><type>article</type><title>Prognostic value of pleural effusion in patients with non-small cell lung cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>American Association for Cancer Research</source><source>Alma/SFX Local Collection</source><creator>SUGIURA, S ; ANDO, Y ; MINAMI, H ; ANDO, M ; SAKAI, S ; SHIMOKATA, K</creator><creatorcontrib>SUGIURA, S ; ANDO, Y ; MINAMI, H ; ANDO, M ; SAKAI, S ; SHIMOKATA, K</creatorcontrib><description>This study was performed to determine whether pleural effusion in patients with advanced non-small cell lung cancer (NSCLC)
has a negative impact on survival. We evaluated 12 prognostic factors in 197 patients with stage IIIB or IV NSCLC. Each factor
was dichotomized, and survival curves calculated by the Kaplan-Meier technique were compared using the log-rank test. The
Cox proportional hazards regression model was used to confirm the significance of each prognostic factor selected by univariate
analysis. We compared the survival times for stage IIIB with pleural effusion with those of stage IIIB without effusion and
stage IV. To determine the impact of the cytological results of the effusion on survival, we compared the survival times for
cytologically positive and negative effusions. Univariate analysis identified eight significant prognostic factors: pleural
effusion, node status, stage, performance status, weight loss, hemoglobin, albumin, and lactate dehydrogenase. Pleural effusion
was selected as a prognostic factor in the multivariate analysis, together with stage, performance status, albumin, and node
status. Median survival times for stage IIIB without effusion, stage IIIB with effusion, and stage IV were 15.3, 7.5, and
5.5 months, respectively (P < 0.0001). Survival time for stage IIIB with effusion was significantly different from that of
stage IIIB without effusion (P = 0.0129) but not from that of stage IV (P = 0.0797). Among patients with effusion, no significant
difference in survival time was observed between cytologically positive and negative effusions. We conclude that pleural effusion
in advanced NSCLC is a prognostic factor. Survival time for stage IIIB with pleural effusion is more similar to that of stage
IV rather than that of stage IIIB without effusion.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>PMID: 9815536</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Carcinoma, Non-Small-Cell Lung - diagnosis ; Carcinoma, Non-Small-Cell Lung - physiopathology ; Female ; Humans ; Lung Neoplasms - diagnosis ; Lung Neoplasms - physiopathology ; Male ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Neoplasm Staging ; Pleural Effusion - pathology ; Pneumology ; Prognosis ; Survival Analysis ; Tumors of the respiratory system and mediastinum</subject><ispartof>Clinical cancer research, 1997-01, Vol.3 (1), p.47-50</ispartof><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,4010</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2594917$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9815536$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SUGIURA, S</creatorcontrib><creatorcontrib>ANDO, Y</creatorcontrib><creatorcontrib>MINAMI, H</creatorcontrib><creatorcontrib>ANDO, M</creatorcontrib><creatorcontrib>SAKAI, S</creatorcontrib><creatorcontrib>SHIMOKATA, K</creatorcontrib><title>Prognostic value of pleural effusion in patients with non-small cell lung cancer</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>This study was performed to determine whether pleural effusion in patients with advanced non-small cell lung cancer (NSCLC)
has a negative impact on survival. We evaluated 12 prognostic factors in 197 patients with stage IIIB or IV NSCLC. Each factor
was dichotomized, and survival curves calculated by the Kaplan-Meier technique were compared using the log-rank test. The
Cox proportional hazards regression model was used to confirm the significance of each prognostic factor selected by univariate
analysis. We compared the survival times for stage IIIB with pleural effusion with those of stage IIIB without effusion and
stage IV. To determine the impact of the cytological results of the effusion on survival, we compared the survival times for
cytologically positive and negative effusions. Univariate analysis identified eight significant prognostic factors: pleural
effusion, node status, stage, performance status, weight loss, hemoglobin, albumin, and lactate dehydrogenase. Pleural effusion
was selected as a prognostic factor in the multivariate analysis, together with stage, performance status, albumin, and node
status. Median survival times for stage IIIB without effusion, stage IIIB with effusion, and stage IV were 15.3, 7.5, and
5.5 months, respectively (P < 0.0001). Survival time for stage IIIB with effusion was significantly different from that of
stage IIIB without effusion (P = 0.0129) but not from that of stage IV (P = 0.0797). Among patients with effusion, no significant
difference in survival time was observed between cytologically positive and negative effusions. We conclude that pleural effusion
in advanced NSCLC is a prognostic factor. Survival time for stage IIIB with pleural effusion is more similar to that of stage
IV rather than that of stage IIIB without effusion.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Non-Small-Cell Lung - diagnosis</subject><subject>Carcinoma, Non-Small-Cell Lung - physiopathology</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - diagnosis</subject><subject>Lung Neoplasms - physiopathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Staging</subject><subject>Pleural Effusion - pathology</subject><subject>Pneumology</subject><subject>Prognosis</subject><subject>Survival Analysis</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEtLxDAUhYso4zj6E4Qs1F0hrybtUgZfMOAsdB2SeDONtGlNWgf_vZEZ3Nx74XxczjknxZJUlSwZFdVpvrGsS8wZPS8uUvrEmHCC-aJYNHXGmFgW220cdmFIk7foW3czoMGhsYM56g6Bc3PyQ0A-oFFPHsKU0N5PLQpDKFOvuw5ZyKObww5ZHSzEy-LM6S7B1XGvivfHh7f1c7l5fXpZ32_KNlubSkqJs42hEpsGUzACO0mdY7Y2VhDRGMkFM8Bqy2pTUUOcIRyDlEYYIYGxVXF3-DvG4WuGNKnepz8zOsAwJyUbwTGmdQavj-BsevhQY_S9jj_qWEHWb466TlZ3LuYYPv1jtGp4Q2TGbg9Y63ft3kdQh7wREuhoW8UUUVyyX_vDcu0</recordid><startdate>19970101</startdate><enddate>19970101</enddate><creator>SUGIURA, S</creator><creator>ANDO, Y</creator><creator>MINAMI, H</creator><creator>ANDO, M</creator><creator>SAKAI, S</creator><creator>SHIMOKATA, K</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19970101</creationdate><title>Prognostic value of pleural effusion in patients with non-small cell lung cancer</title><author>SUGIURA, S ; ANDO, Y ; MINAMI, H ; ANDO, M ; SAKAI, S ; SHIMOKATA, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h265t-221fc9b270b902eb60f72ff3c8bc6169b7463be38c38b52b1fb140e77b6b67e33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Non-Small-Cell Lung - diagnosis</topic><topic>Carcinoma, Non-Small-Cell Lung - physiopathology</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - diagnosis</topic><topic>Lung Neoplasms - physiopathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Staging</topic><topic>Pleural Effusion - pathology</topic><topic>Pneumology</topic><topic>Prognosis</topic><topic>Survival Analysis</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SUGIURA, S</creatorcontrib><creatorcontrib>ANDO, Y</creatorcontrib><creatorcontrib>MINAMI, H</creatorcontrib><creatorcontrib>ANDO, M</creatorcontrib><creatorcontrib>SAKAI, S</creatorcontrib><creatorcontrib>SHIMOKATA, K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SUGIURA, S</au><au>ANDO, Y</au><au>MINAMI, H</au><au>ANDO, M</au><au>SAKAI, S</au><au>SHIMOKATA, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of pleural effusion in patients with non-small cell lung cancer</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>1997-01-01</date><risdate>1997</risdate><volume>3</volume><issue>1</issue><spage>47</spage><epage>50</epage><pages>47-50</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>This study was performed to determine whether pleural effusion in patients with advanced non-small cell lung cancer (NSCLC)
has a negative impact on survival. We evaluated 12 prognostic factors in 197 patients with stage IIIB or IV NSCLC. Each factor
was dichotomized, and survival curves calculated by the Kaplan-Meier technique were compared using the log-rank test. The
Cox proportional hazards regression model was used to confirm the significance of each prognostic factor selected by univariate
analysis. We compared the survival times for stage IIIB with pleural effusion with those of stage IIIB without effusion and
stage IV. To determine the impact of the cytological results of the effusion on survival, we compared the survival times for
cytologically positive and negative effusions. Univariate analysis identified eight significant prognostic factors: pleural
effusion, node status, stage, performance status, weight loss, hemoglobin, albumin, and lactate dehydrogenase. Pleural effusion
was selected as a prognostic factor in the multivariate analysis, together with stage, performance status, albumin, and node
status. Median survival times for stage IIIB without effusion, stage IIIB with effusion, and stage IV were 15.3, 7.5, and
5.5 months, respectively (P < 0.0001). Survival time for stage IIIB with effusion was significantly different from that of
stage IIIB without effusion (P = 0.0129) but not from that of stage IV (P = 0.0797). Among patients with effusion, no significant
difference in survival time was observed between cytologically positive and negative effusions. We conclude that pleural effusion
in advanced NSCLC is a prognostic factor. Survival time for stage IIIB with pleural effusion is more similar to that of stage
IV rather than that of stage IIIB without effusion.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>9815536</pmid><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 1997-01, Vol.3 (1), p.47-50 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79640028 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; American Association for Cancer Research; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Biological and medical sciences Carcinoma, Non-Small-Cell Lung - diagnosis Carcinoma, Non-Small-Cell Lung - physiopathology Female Humans Lung Neoplasms - diagnosis Lung Neoplasms - physiopathology Male Medical sciences Middle Aged Multivariate Analysis Neoplasm Staging Pleural Effusion - pathology Pneumology Prognosis Survival Analysis Tumors of the respiratory system and mediastinum |
| title | Prognostic value of pleural effusion in patients with non-small cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T06%3A37%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20pleural%20effusion%20in%20patients%20with%20non-small%20cell%20lung%20cancer&rft.jtitle=Clinical%20cancer%20research&rft.au=SUGIURA,%20S&rft.date=1997-01-01&rft.volume=3&rft.issue=1&rft.spage=47&rft.epage=50&rft.pages=47-50&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E79640028%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79640028&rft_id=info:pmid/9815536&rfr_iscdi=true |